Literature DB >> 31390173

Efficient and Robust Highly Branched Poly(β-amino ester)/Minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.

Ming Zeng1,2, Fatma Alshehri1,3, Dezhong Zhou1,4, Irene Lara-Sáez1, Xi Wang1, Xiaolin Li1, Sigen A1, Qian Xu1, Jing Zhang1, Wenxin Wang1.   

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe congenital skin fragility disease caused by COL7A1 mutations that result in type VII collagen (C7) deficiency. Herein, we report a synergistic polyplex system that can efficiently restore C7 expression in RDEB keratinocytes. A highly branched multifunctional poly(β-amino ester) (HPAE), termed as HC32-122, was optimized systematically as the high-performance gene delivery vector for keratinocytes, achieving much higher transfection capability than polyethylenimine, SuperFect, and Lipofectamine 2000 without inducing obvious cytotoxicity. Concurrently, a 12 kb length minicircle DNA encoding ∼9 kb full-length COL7A1 (MCC7) devoid of bacterial sequence was biosynthesized as the therapeutic gene. Combining the highly potent polymer and the miniaturized gene structure, HC32-122/MCC7 polyplexes achieve 96.4% cellular uptake efficiency, 4019-fold COL7A1 mRNA enhancement, and robust recombinant C7 expression. Structure-property investigations reveal that HC32-122 can effectively condense MCC7 to form small, uniform, compact, and positively charged spherical nanoparticles with high DNA release flexibility. Moreover, formulation study shows that sucrose is conductive to lyophilized HC32-122/DNA polyplexes for maintaining the transfection capability. Direct frozen polyplexes can maintain full gene transfection capability after one-year storage. High efficiency, biocompatibility, facile manipulation, and long-term stability make the HC32-122/MCC7 system a promising bench-to-bed candidate for treating the debilitating RDEB.

Entities:  

Keywords:  RDEB; highly branched poly(β-amino ester)s; keratinocyte transfection; minicircle DNA; nonviral gene therapy; polymeric nanoparticles; polyplex formulation; type VII collagen

Mesh:

Substances:

Year:  2019        PMID: 31390173     DOI: 10.1021/acsami.9b13135

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  6 in total

1.  Calcium-based nanomaterials and their interrelation with chitosan: optimization for pCRISPR delivery.

Authors:  Navid Rabiee; Mojtaba Bagherzadeh; Amir Mohammad Ghadiri; Mahsa Kiani; Sepideh Ahmadi; Vahid Jajarmi; Yousef Fatahi; Abdullah Aldhaher; Mohammadreza Tahriri; Thomas J Webster; Ebrahim Mostafavi
Journal:  J Nanostructure Chem       Date:  2021-09-22

Review 2.  Integrated Management Strategies for Epidermolysis Bullosa: Current Insights.

Authors:  Haseena Sait; Somya Srivastava; Deepti Saxena
Journal:  Int J Gen Med       Date:  2022-05-24

3.  Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Xianqing Wang; Fatma Alshehri; Darío Manzanares; Yinghao Li; Zhonglei He; Bei Qiu; Ming Zeng; Sigen A; Irene Lara-Sáez; Wenxin Wang
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

Review 4.  Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy.

Authors:  Xuejiao Han; Aqu Alu; Hongmei Liu; Yi Shi; Xiawei Wei; Lulu Cai; Yuquan Wei
Journal:  Bioact Mater       Date:  2022-01-19

5.  Cyanocobalamin Ultraflexible Lipid Vesicles: Characterization and In Vitro Evaluation of Drug-Skin Depth Profiles.

Authors:  Antonio José Guillot; Enrique Jornet-Mollá; Natalia Landsberg; Carmen Milián-Guimerá; M Carmen Montesinos; Teresa M Garrigues; Ana Melero
Journal:  Pharmaceutics       Date:  2021-03-20       Impact factor: 6.321

Review 6.  Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa.

Authors:  Tobias Welponer; Christine Prodinger; Josefina Pinon-Hofbauer; Arno Hintersteininger; Hannelore Breitenbach-Koller; Johann W Bauer; Martin Laimer
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.